Teriparatide therapy and beta-tricalcium phosphate enhance scaffold reconstruction of mouse femoral defects.
暂无分享,去创建一个
E. Schwarz | R. O’Keefe | M. Zuscik | H. Awad | Tulin Dadali | S. Bukata | R. Rosier | G. Bradica | David G. Reynolds | E. Puzas | J. Jacobson | L. Yanoso-Scholl
[1] E. Schwarz,et al. Evaluation of dense polylactic acid/beta-tricalcium phosphate scaffolds for bone tissue engineering. , 2010, Journal of biomedical materials research. Part A.
[2] H. Zreiqat,et al. Beta-tricalcium phosphate exerts osteoconductivity through alpha2beta1 integrin and down-stream MAPK/ERK signaling pathway. , 2010, Biochemical and biophysical research communications.
[3] Paul Childress,et al. Nmp4/CIZ: road block at the intersection of PTH and load. , 2010, Bone.
[4] Qixin Zheng,et al. Porous nano-HA/collagen/PLLA scaffold containing chitosan microspheres for controlled delivery of synthetic peptide derived from BMP-2. , 2009, Journal of controlled release : official journal of the Controlled Release Society.
[5] S. Jatana,et al. Neurologic impairment from ectopic bone in the lumbar canal: a potential complication of off-label PLIF/TLIF use of bone morphogenetic protein-2 (BMP-2). , 2008, The spine journal : official journal of the North American Spine Society.
[6] E. Schwarz,et al. Teriparatide (1‐34 human PTH) regulation of osterix during fracture repair , 2008, Journal of cellular biochemistry.
[7] R. Brower,et al. A case of psoas ossification from the use of BMP-2 for posterolateral fusion at L 4 – L 5 , 2009 .
[8] James D. Kang,et al. Safety Assessment of Intradiscal Gene Therapy II: Effect of Dosing and Vector Choice , 2008, Spine.
[9] S. Goldstein,et al. Parathyroid hormone mediates bone growth through the regulation of osteoblast proliferation and differentiation. , 2008, Bone.
[10] R. T. Allen,et al. Bone Morphogenetic Protein-2 (BMP-2) in the Treatment of Pyogenic Vertebral Osteomyelitis , 2007, Spine.
[11] S. Kakar,et al. Enhanced Chondrogenesis and Wnt Signaling in PTH‐Treated Fractures , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[12] Andrea Giustina,et al. Mechanisms of anabolic therapies for osteoporosis. , 2007, The New England journal of medicine.
[13] A. Vaccaro,et al. Clinical applications of BMP-7/OP-1 in fractures, nonunions and spinal fusion , 2007, International Orthopaedics.
[14] Tetsuji Yamamoto,et al. Human parathyroid hormone (1-34) accelerates natural fracture healing process in the femoral osteotomy model of cynomolgus monkeys. , 2007, Bone.
[15] N. Anand,et al. Adverse swelling associated with use of rh-BMP-2 in anterior cervical discectomy and fusion: a case study. , 2007, The spine journal : official journal of the North American Spine Society.
[16] R. Bittar,et al. BMP-7 (OP-1®) Safety in anterior cervical fusion surgery , 2006, Journal of Clinical Neuroscience.
[17] J. Foley,et al. Parathyroid hormone hormone-related protein and the PTH receptor regulate angiogenesis of the skin. , 2006, The Journal of investigative dermatology.
[18] C. Laurencin,et al. Bone tissue engineering by gene delivery. , 2006, Advanced drug delivery reviews.
[19] Yoshihisa Suzuki,et al. Repair of 20-mm long rabbit radial bone defects using BMP-derived peptide combined with an alpha-tricalcium phosphate scaffold. , 2006, Journal of biomedical materials research. Part A.
[20] M. Holick. PTH (1–34): A Novel Anabolic Drug for the Treatment of Osteoporosis , 2005, Southern medical journal.
[21] T. Einhorn,et al. Effects of low-dose, intermittent treatment with recombinant human parathyroid hormone (1-34) on chondrogenesis in a model of experimental fracture healing. , 2005, Bone.
[22] R. Jilka,et al. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. , 2005, Endocrinology.
[23] S. Goldstein,et al. Anabolic actions of PTH (1-34): use of a novel tissue engineering model to investigate temporal effects on bone. , 2005, Bone.
[24] B. Mitlak,et al. Enhancement of experimental fracture-healing by systemic administration of recombinant human parathyroid hormone (PTH 1-34). , 2005, The Journal of bone and joint surgery. American volume.
[25] S. Komatsubara,et al. Human parathyroid hormone (1-34) accelerates the fracture healing process of woven to lamellar bone replacement and new cortical shell formation in rat femora. , 2005, Bone.
[26] E. Schwarz,et al. A novel murine segmental femoral graft model , 2004, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.
[27] Kevin D Bunting,et al. Safety concerns related to hematopoietic stem cell gene transfer using retroviral vectors. , 2004, Current gene therapy.
[28] M. Karperien,et al. Sclerostin Is an Osteocyte-expressed Negative Regulator of Bone Formation, But Not a Classical BMP Antagonist , 2004, The Journal of experimental medicine.
[29] J. F. Whitfield,et al. Treatment with Parathyroid Hormone hPTH(1-34), hPTH(1-31), and Monocyclic hPTH(1-31) Enhances Fracture Strength and Callus Amount After Withdrawal Fracture Strength and Callus Mechanical Quality Continue to Increase , 2004, Calcified Tissue International.
[30] X. Guo,et al. Trabecular Bone Response to Mechanical and Parathyroid Hormone Stimulation: The Role of Mechanical Microenvironment , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[31] S. Goldstein,et al. Combination of Local and Systemic Parathyroid Hormone Enhances Bone Regeneration , 2003, Clinical orthopaedics and related research.
[32] Z. Xiong,et al. Development of a porous poly(L-lactic acid)/hydroxyapatite/collagen scaffold as a BMP delivery system and its use in healing canine segmental bone defect. , 2003, Journal of biomedical materials research. Part A.
[33] C. Deal,et al. Recombinant human PTH 1-34 (Forteo): an anabolic drug for osteoporosis. , 2003, Cleveland Clinic journal of medicine.
[34] T. Einhorn,et al. Mechanisms for the Enhancement of Fracture Healing in Rats Treated With Intermittent Low‐Dose Human Parathyroid Hormone (1–34) , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[35] C. Rimnac,et al. Fracture resistance of gamma radiation sterilized cortical bone allografts , 2001, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.
[36] P. Aspenberg,et al. Implant fixation enhanced by intermittent treatment with parathyroid hormone. , 2001, The Journal of bone and joint surgery. British volume.
[37] D. Hutmacher,et al. Scaffolds in tissue engineering bone and cartilage. , 2000, Biomaterials.
[38] A. Lalwani,et al. Safety of adeno-associated virus as cochlear gene transfer vector: analysis of distant spread beyond injected cochleae. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.
[39] P. Esbrit,et al. C-terminal parathyroid hormone-related protein increases vascular endothelial growth factor in human osteoblastic cells. , 2000, Journal of the American Society of Nephrology : JASN.
[40] Jeffrey Bonadio,et al. Localized, direct plasmid gene delivery in vivo: prolonged therapy results in reproducible tissue regeneration , 1999, Nature Medicine.
[41] H. Oxlund,et al. Intermittent Parathyroid Hormone (1–34) Treatment Increases Callus Formation and Mechanical Strength of Healing Rat Fractures , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[42] J. Reeve. PTH: A future role in the management of osteoporosis? , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[43] P. Scherer,et al. Accelerated fracture healing. , 1976, Journal of the American Podiatry Association.
[44] Chi-Hwa Wang,et al. Three‐dimensional fibrous PLGA/HAp composite scaffold for BMP‐2 delivery , 2008, Biotechnology and bioengineering.
[45] Amy L Lerner,et al. Micro-computed tomography prediction of biomechanical strength in murine structural bone grafts. , 2007, Journal of biomechanics.
[46] Marcel Karperien,et al. Printed in U.S.A. Copyright © 2000 by The Endocrine Society Expression of Vascular Endothelial Growth Factors and Their Receptors during Osteoblast Differentiation , 2022 .